Alessandro Doria

Professor of Medicine

Harvard Medical School

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Alessandro Doria is a Professor of Medicine at Harvard Medical School, United States. His research focuses on diabetic kidney disease, exploring the efficacy and safety of various therapies, biomarkers associated with kidney disease progression, and the impact of glycemic control on kidney function. Recent publications include studies on the combination therapy of SGLT2 inhibitors and GLP-1 receptor agonists, as well as the genetic variants influencing age at diagnosis of HNF1A-MODY.

Articles (16)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (6)

Vincenzo Trischitta

ITALY

View details

Subramaniam Pennathur

University of Michigan

UNITED STATES

View details

Gaia Chiara Mannino

Magna Graecia University

ITALY

View details

Parker Wilson

Assistant Professor

University of Pennsylvania

UNITED STATES

View details

Marc Froissart

Full Professor, Head Physician

Centre Hospitalier Universitaire Vaudois

SWITZERLAND

View details

Janet McGill

Professor of Medicine

Washington University in St. Louis

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Alessandro Doria

Research Interests

Explore related searches

Contact this professor

About

Articles (16)

Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes and CKD

Combination Therapy with SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease

Classification of Predictors of Rapid Development of Kidney Failure and Short-Term Changes in Concentration of Circulating Proteins

Poor Glycemic Control Is Associated With More Rapid Kidney Function Decline After the Onset of Diabetic Kidney Disease

CKD-EPI and EKFC GFR Estimating Equations: Performance and Other Considerations for Selecting Equations for Implementation in Adults

Associations of Biomarkers of Tubular Injury and Inflammation with Biopsy Features in Type 1 Diabetes

Neuroblastoma suppressor of tumorigenicity 1 is a circulating protein associated with progression to end-stage kidney disease in diabetes

Variants influencing age at diagnosis of HNF1A-MODY

Serum Orotidine: A Novel Biomarker of Increased CVD Risk in Type 2 Diabetes Discovered Through Metabolomics Studies.

Pharmacogenetics of Cardiovascular Prevention in Diabetes: From Precision Medicine to Identification of Novel Targets

Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes.

Contribution of rare variants in monogenic diabetes-genes to early-onset type 2 diabetes.

Diabetes and Myocardial Fibrosis: A Systematic Review and Meta-Analysis.

Pathogenic variants of MODY-genes in adult patients with early-onset type 2 diabetes.

Gain of Function of Malate Dehydrogenase 2 and Familial Hyperglycemia.

Diabetes mellitus correlates with increased biological age as indicated by clinical biomarkers.

Collaborators (6)

Vincenzo Trischitta

Subramaniam Pennathur

Gaia Chiara Mannino

Parker Wilson

Marc Froissart

Janet McGill

Make your next move.